Scinai Immunotherapeutics announced that Ayana Pharma Ltd. signed a five-year Master Service Agreement with the company’s CDMO business unit, Scinai Bioservices. Under the MSA, Scinai will provide drug development and cGMP manufacturing services, including aseptic filling and quality assurance, to Ayana, including encapsulating drug substances of various partners of Ayana into Ayana’s proprietary liposomal drug delivery system.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
